Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: A phase II trial.
Jeremy S. Abramson(Massachusetts General Hospital), Celeste Bello(Moffitt Cancer Center), Robert Redd(Harvard University), Jon Arnason(Beth Israel Deaconess Medical Center), Jeffrey A. Barnes(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center), Tak Takvorian, Ephraim P. Hochberg(Massachusetts General Hospital), Lubomir Sokol(Moffitt Cancer Center), Ann S. LaCasce(Otsuka (Japan)), David Avigan(Beth Israel Deaconess Medical Center), Donna Neuberg(Otsuka (Japan))
Cited by 14
Related Papers
Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
|Science|2017|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k